WIA
AXSM icon

Westbourne Investment Advisors’s Axsome Therapeutics AXSM Stock Holding History

Westbourne Investment Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$3K – 96
2018
Q3 		$3K Buy
+1,000
New +$2.96K ﹤0.01% 164

Other funds holding AXSM

ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Westbourne Investment Advisors's AXSM Position: Q4 2018 in Review

Westbourne Investment Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2018, closing a stake of 1,000 shares — an estimated $3K sold.

Westbourne Investment Advisors first reported a position in AXSM in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 35 funds tracked by Wall St. Rank hold AXSM as of Q4 2018.

  • Westbourne Investment Advisors reported no remaining Axsome Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Westbourne Investment Advisors sold 1,000 Axsome Therapeutics shares in Q4 2018, an estimated $3K.
  • Westbourne Investment Advisors first reported a position in Axsome Therapeutics in Q3 2018 and held it in 1 quarter.
  • Westbourne Investment Advisors's Axsome Therapeutics position peaked at $3K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2018.

Based on Westbourne Investment Advisors's 13F filing for Q4 2018, filed 18 Jan 2019.